Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2007-12-11
2007-12-11
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S143100, C424S144100, C530S387100, C530S388100, C530S388200, C530S388220, C530S388700, C530S388730, C530S388750
Reexamination Certificate
active
10647072
ABSTRACT:
A polypeptide (8F4 molecule) with a T-cell costimulating biological activity is disclosed, as well as monoclonal antibodies against the 8F4 molecule and hybridoma cells which produce the monoclonal antibodies, the use as medicaments of substances which inhibit the biological activity of the 8F4 polypeptide, in particular monoclonal antibodies, natural or synthetic ligands, agonists or antagonists, in particular for preventing or treating diseases which involve the immune system, the use of the 8F4 molecule or cells containing the 8F4 molecule as medicaments, in particular for preventing or treating diseases which involve the immune system, and the use of substances which specifically recognize the 8F4 polypeptide, in particular monoclonal antibodies, natural or synthetic ligands, agonists or antagonists, for diagnosing diseases which involve the immune system.
REFERENCES:
patent: 7125551 (2006-10-01), Kroczek
patent: 2002/0115831 (2002-08-01), Tamatani et al.
patent: 2002/0151685 (2002-10-01), Tamatani et al.
patent: 2002/0156242 (2002-10-01), Tamatani et al.
patent: 2002/0164697 (2002-11-01), Coyle et al.
patent: 2004/0120945 (2004-06-01), Tamatani et al.
patent: 2004/0151720 (2004-08-01), Tamatani et al.
patent: WO 00/46240 (2000-08-01), None
Blazar et al., J. Immunol., 1996, 157: 3250-3259.
U.S. Appl. No. 09/509,283, filed Aug. 11, 2000, Kroczek, (pending claims).
U.S. Appl. No. 09/823,307, filed Apr. 2, 2001, Kroczek, (pending claims).
U.S. Appl. No. 09/972,524, filed Oct. 4, 2001, Kroczek, (pending claims).
Keane-Myers et al., J. Immunol. Jan. 15, 1998; 160:1036-1043.
Mathur et al., Am. J. Respir. Cell Mol. Biol. 1999; 21:498-509.
Ozkaynak et al., Nature Immunol. Jul. 2001; 2(7):591-596.
Willis-Karp M., Immunopharmacol. 2000; 48:263-268.
Chen et al., “Correlation of disease evolution with progressive inflammatory cell activation and migration in the IL-4 transgenic mouse model of atopic dermatitis”, Clin. Exp. Immunol. 139:189-201 (2004).
Ding et al., “Delivering PD-1 inhibitory signal concomitant with blocking ICOS co-stimulation suppresses lupus-like syndrome in autoimmune BXSB mice”, Clin. Immunol. 118:258-267 (2006).
Futamatsu et al., “Attenuation of experimental autoimmune myocarditis by blocking activated T cells through inducible costimulatory molecule pathway”, Cardiovasc. Res. 59:95-104 (2003).
Gonzalo et al., “ICOS is critical for T helper cell-mediated lung mucosal inflammatory responses”, Nature Immunol. 2:597-604 (2001).
Harada et al., “The role of the ICOS-B7h T cell costimulatory pathway in transplantation immunity”, J. Clin. Invest. 112:234-243 (2003).
Hutloff et al., “Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus” Arthritis & Rheumatism 50:3211-3220 (2004).
Iwai et al., “Amelioration of collagen-induced arthritis by blockade of inducible costimulator-B7 homologous protein costimulation”, J. Immunol. 169:4332-4339 (2002).
Iwai et al., “Involvement of inducible costimulator-B7 homologous protein costimulatory pathway in murine lupus nephritis”, J. Immunol. 171:2848-2854 (2003).
Kanai et al., “ICOS costimulation in inflammatory bowel disease”, J. Gastroenterol. 37[Suppl. XIV]:78-81 (2002).
Kawamoto et al., “Expression and function of inducible co-stimulator in patients with systemic lupus erythematosus: possible involvement in excessive interferon-γ and anti-double-stranded DNA antibody production”, Arthritis Res. & Ther. 8:R62 (2006); epub Mar. 22, 2006; doi:10.1186/ar1928.
Keane-Myers et al., “Development of murine allergic asthma is dependent upon B7-2 costimulation”, J. Immunol. 160:1036-1043 (1998).
Mathur et al., “CD28 interactions with either CD80 or CD86 are sufficient to induce allergic airway inflammation in mice”, Am. J. Respir. Cell Mol. Biol. 21:498-509 (1999).
Matsui et al., “Adenovirus-mediated gene transfer of ICOSg fusion protein ameliorates ongoing experimental autoimmune myocarditis”, Human Gene Ther. 14:521-532 (2003).
Nakamura et al., “Acceptance of islet allografts in the liver of mice by blockade of an inducible costimulator”, Transplantation 75:1115-1118 (2003).
Nanji et al., “Costimulation blockade of both inducible costimulator and CD40 ligand induces dominant tolerance to islet allografts and prevents spontaneous autoimmune diabetes in the NOD mouse”, Diabetes 55:27-33 (2006).
Nurieva et al., “Inducible costimulator is essential for collagen-induced arthritis”, J. Clin. Invest. 111:701-706 (2003) Retraction at: J. Clin. Invest. 112:1597 (2003).
Okamoto et al., “Expression and function of the co-stimulator H4/ICOS on activated T cells of patients with rheumatoid arthritis”, J. Rheumatol. 30:1157-1163 (2003).
Rottman et al., “The costimulatory molecule ICOS plays an important role in the immunopathogenesis of EAE”, Nature Immunol. 2:605-611 (2001).
Sato et al., “Hyperexpression of inducible costimulator and its contribution on lamina propria T cells in inflammatory bowel disease”, Gastroenterology 126:829-839 (2004).
Scott et al., “ICOS is essential for the development of experimental autoimmune myasthenia gravis”, J. Neuroimmunol. 153:16-25 (2004).
Totsuka et al., “Amerliorating effect of anti-inducible costimulator monoclonal antibody in a murine model of chronic colitis”, Gastroenterology 124:410-421 (2003).
Usui et al., “The role of the ICOS/B7RP-1 T cell costimulatory pathway in murine experimental autoimmune uveoretinitis”, Eur. J. Immunol. 36:3071-3081 (2006).
Wills-Karp, “Murine models of asthma in understanding immune dysregulation in human asthma”, Immunopharmacol. 48:263-268 (2000).
Yang et al., “Expression and function of inducible costimulator on peripheral blood T cells in patients with systemic lupus erythematosus” Rheumatology 44:1245-1254 (2005); epub Jun. 29, 2005; doi: 10.1093/rheumatology/keh724.
Bundersrepublik Deutschland
Gambel Phillip
Jones Day
Ouspenski Ilia
LandOfFree
Treatment of autoimmune disorders with antibodies to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of autoimmune disorders with antibodies to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of autoimmune disorders with antibodies to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3848626